Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MT-CO2 | P00403 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488302 | 0.90 | ALDH1A1 (0.46) | MAPK14PTGS2PTGS1ALDH1A1HPGD | |
| SCHEMBL4510145 | 0.88 | MAPK14 (0.51) | MAPK14ALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL4500973 | 0.87 | ALDH1A1 (0.46) | MAPK14PTGS2PTGS1ALDH1A1HPGD | |
| SCHEMBL4504173 | 0.86 | GABRA5 (0.48) | MAPK14KDM4ENPC1MAPTKMT2A | |
| SCHEMBL4500969 | 0.86 | GABRA5 (0.48) | MAPK14ALDH1A1HPGDMAPK1SMN1; SMN2 | |
| SCHEMBL4509398 | 0.85 | ALDH1A1 (0.50) | MAPK14PTGS2PTGS1ALDH1A1HPGD | |
| SCHEMBL4500494 | 0.85 | SMN1; SMN2 (0.52) | PTGS2PTGS1ALDH1A1HPGDMAPK1 | |
| SCHEMBL4498333 | 0.85 | ALDH1A1 (0.42) | MAPK14PTGS2PTGS1ALDH1A1HPGD | |
| SCHEMBL4489721 | 0.83 | GABRA5 (0.50) | MAPK14NPSR1MAPK8 | |
| SCHEMBL4487535 | 0.83 | PTGS2 (0.49) | MAPK14PTGS2PTGS1ALDH1A1MT-CO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585874-B2 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-08 | — | — | US | claimed |
| EP-1979350-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE VIA GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | claimed |
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | claimed |
| WO-2007082806-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER’S DISEASE VIA GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | claimed |
| US-7585874-B2 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-09-08 | — | — | US | disclosed |
| EP-1979350-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE VIA GABA RECEPTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-15 | — | — | EP | disclosed |
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-02 | — | — | US | disclosed |
| WO-2007082806-A1 | ARYL-ISOXAZOL-4-YL-IMIDAZO[1,2-A]PYRIDINE USEFUL FOR THE TREATMENT OF ALZHEIMER’S DISEASE VIA GABA RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179178-A1 | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine derivatives | GABRA5, GABRA4, GABRA1 | MAPK14 3887/4885PTGS2 3313/4885PTGS1 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.